Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19758278rdf:typepubmed:Citationlld:pubmed
pubmed-article:19758278lifeskim:mentionsumls-concept:C0019163lld:lifeskim
pubmed-article:19758278lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19758278lifeskim:mentionsumls-concept:C0008972lld:lifeskim
pubmed-article:19758278lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:19758278lifeskim:mentionsumls-concept:C0209738lld:lifeskim
pubmed-article:19758278lifeskim:mentionsumls-concept:C0524909lld:lifeskim
pubmed-article:19758278lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:19758278lifeskim:mentionsumls-concept:C0243161lld:lifeskim
pubmed-article:19758278lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:19758278lifeskim:mentionsumls-concept:C1880019lld:lifeskim
pubmed-article:19758278pubmed:issue4lld:pubmed
pubmed-article:19758278pubmed:dateCreated2010-5-7lld:pubmed
pubmed-article:19758278pubmed:abstractTextThe cessation criteria for lamivudine treatment vary in published articles and their results are contradictory, especially factors predicting relapse. To clarify these contradictions, this long-term follow-up study of 125 Chinese hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients was designed with stringent cessation criterion. All patients received lamivudine and achieved HBeAg seroconversion (group A, n = 82) or loss (group B, n = 43) with undetectable hepatitis B virus (HBV) DNA by PCR assay during the treatment. Lamivudine was withdrawn >or=6 months after HBeAg seroconversion/loss occurred. The median treatment durations were 24 (12-54) months and 36 (18-89) months in group A and group B, respectively. Patients were followed up for median 24 (2-84) months. The cumulative relapse (defined as serum HBV DNA >or=10(4) copies/mL) rates in the two groups at months 12, 24, 36 and 48 were 23.4%vs 35.0%, 25.0%vs 37.7%, 25.0%vs 41.1% and 29.4%vs 41.1%, respectively (log-rank test, P = 0.119). For patients whose total treatment duration >or=18 months in group A, the cumulative relapse rates at months 12, 24, 36 and 48 were 18.3%, 20.1%, 20.1% and 25.1%, which was significantly lower than those with a shorter duration (log-rank test, P = 0.002). The mean age and median total duration were statistically different between relapsers and nonrelapsers in group A (33.9 +/- 13.6 vs 23.1 +/- 11.0 years, P < 0.001 and 24 vs 26 months, P = 0.003). Cox regression revealed that age was the only predictive factor for relapse (RR, 1.069; 95% CI, 1.032-1.106, P < 0.001). Patients aged <30 years relapsed less frequently in 5 years (12.3%vs 53.5%, P = 0.001). In conclusion, for patients who maintained HBeAg seroconversion for >or=6 months and total duration for >or=18 months, lamivudine withdrawal is a reasonable option. Prolonged treatment may be required for patients aged greater than 30 years to reduce relapse.lld:pubmed
pubmed-article:19758278pubmed:languageenglld:pubmed
pubmed-article:19758278pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19758278pubmed:citationSubsetIMlld:pubmed
pubmed-article:19758278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19758278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19758278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19758278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19758278pubmed:statusMEDLINElld:pubmed
pubmed-article:19758278pubmed:monthAprlld:pubmed
pubmed-article:19758278pubmed:issn1365-2893lld:pubmed
pubmed-article:19758278pubmed:authorpubmed-author:LisHHlld:pubmed
pubmed-article:19758278pubmed:authorpubmed-author:WangLLlld:pubmed
pubmed-article:19758278pubmed:authorpubmed-author:SunT PTPlld:pubmed
pubmed-article:19758278pubmed:authorpubmed-author:ZhangZ-HZHlld:pubmed
pubmed-article:19758278pubmed:authorpubmed-author:SuWeiWlld:pubmed
pubmed-article:19758278pubmed:authorpubmed-author:WangY-ZYZlld:pubmed
pubmed-article:19758278pubmed:authorpubmed-author:WangJ-BJBlld:pubmed
pubmed-article:19758278pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19758278pubmed:volume17lld:pubmed
pubmed-article:19758278pubmed:ownerNLMlld:pubmed
pubmed-article:19758278pubmed:authorsCompleteYlld:pubmed
pubmed-article:19758278pubmed:pagination298-304lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:meshHeadingpubmed-meshheading:19758278...lld:pubmed
pubmed-article:19758278pubmed:year2010lld:pubmed
pubmed-article:19758278pubmed:articleTitleStringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients.lld:pubmed
pubmed-article:19758278pubmed:affiliationDepartment of Infectious Diseases and Hepatology, Second Hospital of Shandong University, Shandong University, Jinan, China. wlcrb@sdu.edu.cnlld:pubmed
pubmed-article:19758278pubmed:publicationTypeJournal Articlelld:pubmed